Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II: Randomized Neoadjuvant Treatment of Oral Cavity Cancer With Spatially Fractionated Proton Radiotherapy and Immunotherapy (OSPRI)

NCT07783581 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT07783581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07783581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II: Randomized Neoadjuvant Treatment of Oral Cavity Cancer With Spatially Fractionated Proton Radiotherapy and Immunotherapy (OSPRI)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 7, 2026
Completion date
April 1, 2030
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced oral cavity squamous cell carcinoma, locally recurrent oral cavity squamous cell carcinoma, oral cavity squamous cell carcinoma